The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients.

MLA

Getts, Daniel R., et al. “The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human Αβ T Cell Receptor Antibody, in Renal Transplant Patients.” Clinical Pharmacokinetics, vol. 53, no. 7, July 2014, pp. 649–57. EBSCOhost, https://doi.org/10.1007/s40262-014-0138-1.

APA

Getts, D. R., Kramer, W. G., Wiseman, A. C., & Flechner, S. M. (2014). The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients. Clinical Pharmacokinetics, 53(7), 649–657. https://doi.org/10.1007/s40262-014-0138-1

Chicago

Getts, Daniel R, William G Kramer, Alexander C Wiseman, and Stuart M Flechner. 2014. “The Pharmacokinetics and Pharmacodynamics of TOL101, a Murine IgM Anti-Human Αβ T Cell Receptor Antibody, in Renal Transplant Patients.” Clinical Pharmacokinetics 53 (7): 649–57. doi:10.1007/s40262-014-0138-1.